BioTuesdays

Category - Markets

Knight Therapeutics
Markets

RBC starts Knight Therapeutics at OP; PT $9.50

RBC Capital Markets launched coverage of Knight Therapeutics (TSX:GUD) with an “outperform” rating and price target of $9.50. The stock closed at $7.79 on April 20. Knight’s focus is on the licensing and...

April 23, 2018
Ovid Therapeutics
Markets

Ladenburg starts Ovid Therapeutics at buy; PT $27

Ladenburg Thalmann initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with a “buy” rating and $27 price target. The stock closed at $10.14 on April 19. Ovid is developing two clinical-stage candidates: OV101, a GABA...

April 20, 2018
Sientra Logo
Markets

Leerink resumes coverage of Sientra at OP; PT $19

Leerink resumed coverage of Sientra (NASDAQ:SIEN) with an “outperform” rating and $19 price target. The stock closed at $11.98 on April 19. Leerink suspended coverage of Sientra in 2015 following a CE Mark suspension...

April 20, 2018
IntriCon Logo
Markets

Stifel starts IntriCon at buy; PT $35

Stifel initiated coverage of IntriCon (NASDAQ:IIN) with a “buy” rating and $35 price and also added IntriCon to the Stifel Select List. The stock closed at $19.60 on April 16. “In our opinion, IntriCon is one of the...

April 17, 2018
Viveve Medical Logo
Markets

Stifel starts Viveve Medical at buy; PT $6

Stifel launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and $6 price target. The stock closed at $3.36 on April 16. Viveve is focused on development and marketing the Viveve system and the Geneveve...

April 16, 2018
Cutera
Markets

Stifel starts Cutera at hold; PT $55

Stifel initiated coverage of Cutera (NASDAQ:CUTR) with a “hold” rating and price target of $55. The stock closed at $54.60 on April 16. Cutera develops and manufactures products used various aesthetic procedures...

April 16, 2018
NeoGenomics
Markets

BTIG ups NeoGenomics to buy; PT $11

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral” with a price target of $11, saying that with a cleaner slate, it expects the shares to outperform. The stock closed at $8.49 on April 13. Analyst Dr. Sean...

April 16, 2018
Apollo Endosurgery
Markets

Piper starts Apollo Endosurgery at overweight; PT $8

Piper Jaffray launched coverage of Apollo Endosurgery (NASDAQ:LAPEN) with an “overweight” rating and $8 price target. The stock closed at $5.85 on April 12. Apollo is focused on bariatric and general surgery procedures...

April 13, 2018
Aptevo Therapeutics
Markets

Roth start Aptevo at buy; PT $12

Roth Capital Partners initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and price target of $12. The stock closed at $3.28 on April 11. “In our view, Aptevo remains under the Street’s...

April 12, 2018
vTv Therapeutics Logo
Markets

Stifel cuts vTv Therapeutics to hold; PT to $1 from $12

Stifel downgraded vTv Therapeutics (NASDAQ:VTVT) to “hold” from “buy” and slashed its price target to $1 from $12 after the company reported negative top line results from its Phase 3 STEADFAST study in mild Alzheimer’s...

April 10, 2018